Table 1 Table of schedule of events

 Phone screen (Eligibility)

X

 Informed consent for medical screen

X

 Medical screen/assessment (Eligibility)

X

 Informed consent for main study participation

X

 Allocation

X

 Medication [Nabiximols or placebo] dispensed

X

X

X

X

X

X

X

X

X

X

X

X

X

 Nursing clinical reviews

X

X

X

X

X

X

X

X

X

X

X

X

X

 Medical clinical reviews

X

X

X

X

X

 CBT sessions

X

X

X

X

X

X

 Urine drug screen

X

X

X

X

X

X

X

X

X

X

X

X

X

X

 Research Interviews. Variables include:

Cannabis & other substance use (TLFB), CWS, AEs, Aberrant medication behaviour (mod ORBIT), SF-6D (QOL), WHO Health and Performance Questionnaire: CT version, SF-36 (Physical and Mental health), DASS-21, PHQ-15, OTI: BPI, Crime, Satisfaction, Test blind (week 12 only)

X

X

X

X

X

 Clinical (Nursing/medical) Review variables:

AEs, Aberrant medication behaviour (weigh bottles), ratings dose adequacy, ATOP & BPRS at 4 week intervals, reason for study termination Wk 24.

X

X

X

X

X

X

X

X

X

X

X

X

 Cognitive assessment. Variables include

Blood samples (pre/post cognitive testing), Cognitive testing, Abuse liability (subjective liking, strength, Physiological response)

X

X

X